Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 15 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/1/1999 First Published: 12/1/1998


1.		Phase III Randomized Study of Oral Fluorouracil (5-FU) Plus 776C85 Versus Intravenous 5-FU Plus Leucovorin Calcium as First Line Therapy in Patients with Metastatic Colorectal Cancer (Summary Last Modified 05/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GW-FUMA3008

Last Modified: 5/31/2007 First Published: 6/1/1999


2.		Phase III Randomized Study of Oral Fluorouracil (5-FU) and Eniluracil Versus Continuous Infusion 5-FU in Patients With Advanced Colorectal Cancer (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-5296 NCT00003873, E5296

Last Modified: 8/1/2000 First Published: 3/1/2000


3.		Phase I/II Study of Concurrent Radiotherapy With Ethynyluracil, Fluorouracil and Hydroxyurea in Patients With Advanced Oral Cancer (Summary Last Modified 08/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NU-V95N4 NCI-G00-1680, NCT00004901

Last Modified: 1/1/2001 First Published: 4/1/2000


4.		Phase I/II Study of Eniluracil, Fluorouracil, and Oxaliplatin in Patients With Previously Treated Advanced Colorectal Cancer (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				NYU-9907 NCI-G00-1718, NCT00005050

Last Modified: 8/9/2004


5.		Phase II Study of Oral Ethynyluracil, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Colorectal Carcinoma (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CLB-9683 CALGB-9683

Last Modified: 4/1/1900


6.		Phase II Study of a Seven Day Regimen of Oral Ethynyluracil (776C85) Plus a Five Day Regimen of Oral Fluorouracil (5-FU) in Patients with Unresectable or Metastatic Colorectal Carcinoma Who Have Had No Prior Systemic Chemotherapy (Summary Last Modified 04/00)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCCTG-954651 NCCTG-95-46-51

Last Modified: 4/20/2007


7.		Phase II Study of Fluorouracil (5-FU) Plus Ethynyluracil (776C85) in Patients with Metastatic Pancreatic Adenocarcinoma (Summary Last Modified 05/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				SWOG-9629 S9629

Last Modified: 7/1/1999


8.		Phase II Study of Ethynyluracil (776C85) and Fluorouracil (5-FU) in Advanced or Recurrent Squamous Cell Cancer of the Head and Neck (Summary Last Modified 07/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				16 and over				Pharmaceutical / Industry				CAN-NCIC-IND105 GW-564/070, IND105

Last Modified: 3/27/2003


9.		Phase II Study of Oral Fluorouracil Plus Ethynyluracil in Patients With Advanced Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				E-4296 E4296

Last Modified: 11/1/2000 First Published: 4/1/1998


10.		Phase II Study of Fluorouracil Plus Ethynyluracil (776C85) in Patients With Advanced Fluorouracil Resistant Colorectal Cancer (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 18				NCI				SWOG-S9635 NCT00003254, S9635

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute